Submit a Manuscript to the Journal

Journal of Enzyme Inhibition and Medicinal Chemistry

For an Article Collection on

β-Lactamases in Antibacterial Therapy and Diagnostics

Manuscript deadline
12 January 2024

Cover image - Journal of Enzyme Inhibition and Medicinal Chemistry

Article collection guest advisor(s)

Dr Jean-François Hernandez , Institut des Biomolécules Max Mousseron
[email protected]

Submit an ArticleVisit JournalArticles

β-Lactamases in Antibacterial Therapy and Diagnostics

Alarmingly growing bacterial resistance to antibiotics might become one of the most worrying threats to Public Health worldwide. In this context, WHO has published a list of resistant bacteria for which new antibiotics are urgently needed. Main priority concerns Gram-negative opportunistic pathogens responsible of severe nosocomial infections, which are resistant to the invaluable β-lactam antibiotics carbapenems and 3rd generation cephalosporins through the production of β-lactamases (BLs). These carbapenem-hydrolyzing BLs can be separated in two large families according to their catalytic mechanism. They are either serine-hydrolases (SBLs, e.g. KPC-type, OXA-48) or metallo-hydrolases (MBLs, e.g. VIM-, NDM-, IMP- types). Several inhibitors of SBLs only (e.g. avibactam) were recently marketed in association with β-lactam antibiotics, but resistances to these combinations have already been reported. In the case of MBLs, no inhibitor has received FDA approval yet, and only a few compounds are in preclinical or clinical stages (e.g. taniborbactam). Therefore, efforts are still needed to expand the therapeutic arsenal to preserve the precious carbapenems and last-generation cephalosporins.

In contrast, BLs might be exploited in the design of prodrugs or diagnostic tools, thanks to their substrate selectivity and the absence of β-lactam-hydrolysing activity in eukaryotic cells. In this strategy, β-lactam-based molecules undergo fragmentation upon BL cleavage to release either an antibacterial species or a reporter molecule in the bacteria.

The goal of this special issue is to provide an overview of the latest advances in BL inhibition and in the exploitation of BLs in targeted antibacterial therapy and diagnostic.

Reviews and original articles from experts in the fields of medicinal chemistry, biochemistry, microbiology, structural biology, biotechnology, and pharmaceutics are welcome.

Subtopics include, but are not limited to: inhibitors of either serine- (SBL) or metallo-b-lactamases (MBL), or both (mixed inhibitors); b-Lactamase-activated antibacterial drugs (prodrug) and b-lactamase-activated probes (diagnostic).

Benefits of publishing open access within Taylor & Francis

Global marketing and publicity, ensuring your research reaches the people you want it to.

Article Collections bring together the latest research on hot topics from influential researchers across the globe.

Rigorous peer review for every open access article.

Rapid online publication allowing you to share your work quickly.

All manuscripts submitted to this Article Collection will undergo desk assessment and peer-review as part of our standard editorial process. Guest Advisors for this collection will not be involved in peer-reviewing manuscripts unless they are an existing member of the Editorial Board. Please review the journal Aims and Scope and author submission instructions prior to submitting a manuscript.